Home › Funds › Lion Point Capital, LP › MLTX
Lion Point Capital, LP position in MLTX
MOONLAKE IMMUNOTHERAPEUTICS · Health Care
Lion Point Capital, LP reported holding 67,500 shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS) in its Q2 2026 13F filing — a position valued at US$1.3M, representing 6.29% of its reported portfolio and ranking #3 among its reported holdings. Lion Point Capital, LP has disclosed MLTX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's MLTX position evolved
Lion Point Capital, LP first disclosed a stake in MLTX in Q3 2025 at 67,500 shares (US$484K). The position peaked in Q2 2026 at 67,500 shares, worth US$1.3M. Across 4 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 67,500 shares valued at US$1.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 67.50K | $483.98K | New |
| Q4 2025 | 67.50K | $889.65K | Hold |
| Q1 2026 | 67.50K | $1.26M | Hold |
| Q2 2026 | 67.50K | $1.31M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MLTX and 13F data
MLTX (MOONLAKE IMMUNOTHERAPEUTICS) is a Health Care company. 30 other funds we track also report a position in MLTX — the largest reported positions include BVF INC/IL (US$311.5M), Deep Track Capital, LP (US$136.3M), Cormorant Asset Management, LP (US$62.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MLTX
- BVF INC/IL 16.00M sh · $311.54M · Q2 2026
- Deep Track Capital, LP 7.00M sh · $136.27M · Q2 2026
- Cormorant Asset Management, LP 3.21M sh · $62.41M · Q2 2026
- Logos Global Management LP 2.67M sh · $52.08M · Q2 2026
- Weiss Asset Management LP 2.58M sh · $50.27M · Q2 2026
- MPM BioImpact LLC 1.61M sh · $31.29M · Q2 2026
- Vivo Capital, LLC 1.40M sh · $27.26M · Q2 2026
- GREAT POINT PARTNERS LLC 855.81K sh · $16.66M · Q2 2026
- Trails Edge Capital Partners, LP 750.00K sh · $14.60M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held MLTX?
Lion Point Capital, LP has disclosed MLTX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Lion Point Capital, LP's current position in MLTX?
As of Q2 2026, Lion Point Capital, LP holds 67.50K shares of MLTX (MOONLAKE IMMUNOTHERAPEUTICS), valued at $1.31M, representing 6.29% of its reported portfolio and ranking #3.
Has Lion Point Capital, LP been buying or selling MLTX?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in MLTX. The position peaked in Q2 2026 at 67.50K shares.
Which other funds hold MLTX?
Other major institutional holders of MLTX include BVF INC/IL, Deep Track Capital, LP, Cormorant Asset Management, LP, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.